Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Nat Med. 2021 Oct 18;27(11):1921–1927. doi: 10.1038/s41591-021-01521-4

Figure 2: CH detected prior to the diagnosis of hematologic malignancies in WES cohort.

Figure 2:

Rows indicate CHIP genes or mCAs, columns indicate individuals who developed hematologic malignancy between 6 months and 12 years after blood sample collection for sequencing (n=579), and the shells indicate number of CH alterations. The individuals are grouped by the type of first diagnosis of hematologic malignancies. Only CHIP genes and mCAs detected among individuals with an incident hematologic malignancy are shown. LOH, copy-neutral loss-of-heterozygosity; del, copy loss (deletion); gain, copy gain; tri, trisomy (gain of whole chromosome); MPN, myeloproliferative neoplasm; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; MM, multiple myeloma; MGUS, monoclonal gammopathy of undetermined significance; NHL, non-Hodgkin’s lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; WM, Waldenstrom’s macroglobulinaemia; HL, Hodgkin’s lymphoma.